These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38426508)

  • 1. A Novel NMR-Based Protocol to Screen Ultralow Molecular Weight Fragments.
    Favaro A; Sturlese M
    J Med Chem; 2024 Mar; 67(5):3874-3884. PubMed ID: 38426508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.
    Silvestre HL; Blundell TL; Abell C; Ciulli A
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12984-9. PubMed ID: 23872845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment Hits: What do They Look Like and How do They Bind?
    Giordanetto F; Jin C; Willmore L; Feher M; Shaw DE
    J Med Chem; 2019 Apr; 62(7):3381-3394. PubMed ID: 30875465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening Ligands by X-ray crystallography.
    Davies DR
    Methods Mol Biol; 2014; 1140():315-23. PubMed ID: 24590727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid Screening Approach for Very Small Fragments: X-ray and Computational Screening on FKBP51.
    Draxler SW; Bauer M; Eickmeier C; Nadal S; Nar H; Rangel Rojas D; Seeliger D; Zeeb M; Fiegen D
    J Med Chem; 2020 Jun; 63(11):5856-5864. PubMed ID: 32420743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR characterization of weak interactions between RhoGDI2 and fragment screening hits.
    Liu J; Gao J; Li F; Ma R; Wei Q; Wang A; Wu J; Ruan K
    Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt A):3061-3070. PubMed ID: 27721047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment screening and HIV therapeutics.
    Bauman JD; Patel D; Arnold E
    Top Curr Chem; 2012; 317():181-200. PubMed ID: 21972022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based screening by protein-detected NMR spectroscopy.
    Kerber PJ; Nuñez R; Jensen DR; Zhou AL; Peterson FC; Hill RB; Volkman BF; Smith BC
    Methods Enzymol; 2023; 690():285-310. PubMed ID: 37858532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
    Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
    Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress in the fragment-based drug discovery].
    Ren J; Li J; Shi F; Wang X; He JH; Xu YC; Zhang NX; Xiong B; Shen JK
    Yao Xue Xue Bao; 2013 Jan; 48(1):14-24. PubMed ID: 23600136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation.
    Fuglestad B; Kerstetter NE; Bédard S; Wand AJ
    ACS Chem Biol; 2019 Oct; 14(10):2224-2232. PubMed ID: 31550881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.